Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-04
2000-10-24
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31505
Patent
active
061368121
ABSTRACT:
The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.
REFERENCES:
patent: 5252584 (1993-10-01), Carling et al.
patent: 5268378 (1993-12-01), Baker et al.
patent: 5342946 (1994-08-01), Hamilton et al.
patent: 5356902 (1994-10-01), Ornstein
patent: 5364876 (1994-11-01), Hamilton
patent: 5376748 (1994-12-01), Carling et al.
patent: 5395827 (1995-03-01), Rzeszotarski et al.
patent: 5399696 (1995-03-01), Arnold et al.
patent: 5407935 (1995-04-01), Bigge et al.
patent: 5420155 (1995-05-01), Kulagowski
patent: 5426106 (1995-06-01), Kulagowski
patent: 5446051 (1995-08-01), Ornstein
patent: 5475008 (1995-12-01), Carling et al.
patent: 5504085 (1996-04-01), Jacobsen et al.
patent: 5510338 (1996-04-01), Hamilton
patent: 5514680 (1996-05-01), Weber et al.
patent: 5519019 (1996-05-01), Andrasi et al.
patent: 5521174 (1996-05-01), Andrasi et al.
patent: 5527810 (1996-06-01), Ornstein
patent: 5532236 (1996-07-01), Jacobsen et al.
patent: 5559106 (1996-09-01), Jacobsen et al.
patent: 5559125 (1996-09-01), Kulagowski et al.
patent: 5580877 (1996-12-01), MacLeod
patent: 5606062 (1997-02-01), Huff
patent: 5614508 (1997-03-01), Nikam
patent: 5614532 (1997-03-01), Carling et al.
patent: 5620979 (1997-04-01), Weber et al.
patent: 5622952 (1997-04-01), Weber et al.
patent: 5631373 (1997-05-01), Cai et al.
patent: 5639751 (1997-06-01), Andrasi et al.
patent: 5654303 (1997-08-01), Kornberg et al.
Albin R.L., Greenamyre J.T. (1992) Alternative Excitotoxic Hypothesis, Neurology, 42, pp. 733-737.
Greenamyre J.T., et al.(1994) Antiparkinsonian Effects of Remacemide Hydrochloride, A Glutamate Antagonist, in Rodent and Primate Models of Parkinson's Disease, Annals of Neurology, 35, pp 655-661.
Greenamyre J.T. (1996) Pharmacological Pallidotomy With Glutamate Antagonists, Annals of Neurolgy, 39(5): pp. 557-558.
Klockgether T., et al. (1991) The AMPA Receptor Antagonist NBQX Has Antiparkinsonian Effects in Monoamine-depleted Rats and MPTP-Treated Monkeys, Annals of Neurology, 30, pp. 717-723.
Papa S.M. and Chase T.N. (1996) Levodopa-Induced Dyskinesias Improved by a Glutamate Antagonist in Parkinsonian Monkeys, Annals of Neurology, 39(5): pp. 574-578.
Srivastava et al, Chemical Abstracts, vol. 107, abstract No. 175980, 1986.
Chenard Bertrand L.
Menniti Frank S.
Welch Willard M.
Ginsberg Paul H.
Jarvis William R. A.
Konstas Kristina L.
Pfizer Inc
Richardson Peter C.
LandOfFree
Methods of administering AMPA receptor antagonists to treat dysk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering AMPA receptor antagonists to treat dysk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering AMPA receptor antagonists to treat dysk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1964278